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(57) ABSTRACT
The present invention relates to a method for promoting
cardiac tissue repair comprising administering to the cardiac
tissue a therapeutically effective amount of an angiogenic
thrombin derivative peptide and/or inhibiting or reducing
vascular occlusion or restenosis. The invention also relates
to methods of stimulating revascularization. In yet another
embodiment, the invention relates to the use of thrombin
derivative peptides in the manufacture of a medicamentfor
the methods described herein.
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METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
RELATED APPLICATIONS
This application is a continuation-in-part of U.S. appli-
cation Ser. No. 09/904,090,filed Jul. 12, 2001, which claims
the benefit of U.S. Provisional Application Ser. No. 60/217,
583, filed Jul. 12, 2000, the entire teachings of which are
incorporated herein by reference.
GOVERNMENT SUPPORT
The invention was supported, in whole or in part, by a
grant R43 HL64508 from NationalInstitutes of Health. The
Government has certain rights in the invention.
BACKGROUND OF THE INVENTION
Human alpha-thrombin appears to have growth-
promoting activity for a wide variety of cells from various
tissues. For example, alpha-thrombin has been shown to
initiate proliferation of fibroblastic cells in culture without
addition of serum or other purified growth factors, to syn-
ergize with epidermal growth factor in certain hamster
fibroblasts and human endothelial cells, to initiate cell
division or DNAsynthesis in mammalian lens epithelial and
spleen cells and actuate monocytes and neutrophils. Yet, the
use of thrombin as a growth factor and its potential impor-
tance to wound healing has not been widely acclaimed. In
part, this may be due to the complexity of thrombin’s
involvement with coagulation, platelet activation, and ini-
tiation of cell proliferation as well as to the complex
regulation of thrombin and thrombin-like molecules by
serum protease inhibitors and by cell-released protease
nexins. This complexity and high degree of physiologic
regulation, however, supports the potential importance of
this initiation pathway in wound healing.
Thrombin may also play a role in both normal revascu-
larization and migration ofcells from the bloodto thesite of
injury and the abnormal metastasis and angiogenesis asso-
ciated with tumors. The ability of thrombin to increase
endothelial cell proliferation and alter the barrier function of
blood vessels may contribute to angiogenesis and inflam-
mation at sites of tissue injury.
Thrombin derivative peptides have been described by the
present inventors for the agonizing and antagonizing throm-
bin and/or thrombin receptor activity, such as in the treat-
ment of wounds. U.S. Pat. No. 5,500,412 or 5,352,664, the
contents of which are incorporated herein by reference in
their entirety. However, the patent does not teach the novel
use of the thrombin derivative peptides for the treatment of
damaged cardiac tissue, for revascularization, or for inhibi-
tion of vascular occlusion and restenosis.
SUMMARYOF THE INVENTION
The invention relates to methods for promoting cardiac
tissue or myocardium repair, promoting vascularization or
inhibiting vascular occlusion or restenosis. The method
comprises administering to the cardiac tissue or blood
vessels a therapeutically effective amount of an angiogenic
thrombin derivative peptide. In a preferred embodiment, the
peptide is a peptide described in U.S. Pat. No. 5,500,412 or
5,352,664, the contents of which are incorporated herein by
reference in their entirety. For example, the peptide can
preferably comprises a thrombin receptor binding domain
having the sequence Arg-Gly-Asp-Ala (SEQ ID NO:1); and













esterase conserved sequences comprise Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:2). In yet
a more preferred embodiment, the thrombin derivative pep-
tide comprises the amino acid sequence: Ala-Gly-Tyr-Lys-
Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-
Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:3), such as a
peptide which consists of the amino acid sequence Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 3). The
peptide having the sequence of SEQ ID NO.3 is also
referred to herein as “TP508”).
Alternatively, the thrombin derivative peptide is a physi-
ologically functional equivalent of the thrombin derivative
peptide comprising the amino acid sequence of SEQ ID NO:
3. In a particular embodiment, the thrombin derivative
peptide comprises the modified amino acid sequence: Ala-
Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-
Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH.(SEQ ID NO:
4). In a particular embodiment, the thrombin derivative




The peptide can preferably be administered during or
following cardiac surgery, for example by direct or catheter-
mediated injection into damaged or ischemic cardiac tissue
as a soluble peptide or in a sustained release formulation.
The invention also relates to a method of stimulating
revascularization or vascular endothelial cell proliferation
comprising administering to cardiac tissue a therapeutically
effective amount of an angiogenic thrombin derivative
peptide, as described herein.
The invention also relates to a method of preventing
vascular occlusion or restenosis comprising administering a
therapeutically effective amount of the angiogenic thrombin
receptor binding peptide to blood vessels, for example, by
systemic injection, by delivering the peptides to sites of
vascular injury by catheter, or by attachment of the peptide
to stents.
BRIEF DESCRIPTION OF THE FIGURES
FIG.1 is a graph showing that increasing concentrations
of TP508 (peptide having the amino acid sequence of SEQ
ID NO:3) stimulates the proliferation of human microvas-
cular endothelial cells in vitro. The graph shows the cell
count 48 hours after being administered various concentra-
tions of TP508 (indicated in g/ml).
FIG.2 is a graph showing that increasing concentrations
of TP508 stimulates the migration of microvascular endot-
helial cells on plastic. The graph shows the distance
migrated by the cells after being administered various con-
centrations of TP508 (indicated in ug/ml).
FIG.3 is a graph showing changesin cardiac function in
TP508 treated and control pigs in porcine model of cardiac
ischemia.
DETAILED DESCRIPTION OF THE
INVENTION
Cardiovascular diseases are generally characterized by an
impaired supply of blood to the heart or other target organs.
Myocardial infarction (MI) result from narrowed or blocked
coronary arteries in the heart which starves the heart of
needed nutrients and oxygen. When the supply of blood to
the heart is compromised, cells respond by generating com-
pounds that induce the growth of new blood vessels soas to
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increase the supply of blood to the heart. These new blood
vessels are called collateral blood vessels. The process by
which new blood vessels are induced to grow out of the
existing vasculature is termed angiogenesis, and the sub-
stances that are produced bycells to induce angiogenesis are
the angiogenic factors.
When heart muscle is deprived of oxygen and nutrients
due to vascular occlusion, the heart muscle tissue becomes
ischemic andloosesits ability to contract and function. This
loss of function maybe restored by natural signals from the
ischemic heart muscle that induce angiogenic revasculariza-
tion through developmentof collateral vessels that bypass
the occlusion. This revascularization or angiogenesis
involves the stimulation of endothelial cell proliferation and
migration and budding off of new blood vessels. In many
cases, however, the natural signals are not sufficient to cause
collateral vessel growth and the ischemic tissue can become
fibrotic or necrotic. If this process is not reversed by
procedures to open the occluded vessels or further induction
of collateral blood vessels, the heart may become totally
disfunctional and require transplantation.
The peptides described herein can be employed to induce
angiogenic proliferation and migration of endothelial cells
resulting in formation of new capillaries and collateral
vessels to help restore function to damaged or ischemic heart
tissue. These peptides may preferably be directly injected
into or applied to heart tissue during open chest procedures
for bypass surgery or insertion of ventricular assist devices
or delivered by catheter injection into the heart as a soluble
peptide or in a sustained release formulation.
Endothelial cell proliferation, such as that which occurs in
angiogenesis, is also useful in preventing or inhibiting
restenosis following balloon angioplasty. The balloon angio-
plasty procedure often injures the endothelial cells lining the
inner walls of blood vessels and disrupts the integrity of the
vessel wall. Smooth muscle cells and inflammatory cells
often infiltrate into the injured blood vessels causing a
secondary obstruction in a process known as restenosis.
Stimulation of the proliferation and migration of the endot-
helial cells located at the periphery of the balloon-induced
damaged area in order to cover the luminal surface of the
vessel with a new monolayer of endothelial cells would
potentially restore the original structure of the blood vessel.
Preferably, endothelialization comprises
re-endothelialization after angioplasty, to reduce, inhibit or
prevent restenosis. Those of skill in the art will recognize
that patients treated according to the methodsof the present
invention may be treated with or without a stent.
An inflatable balloon catheter with peptide coating the
balloon or a catheter that directly injects the peptide into the
wall of the vessel may also be employed to deliver the
substance to a targeted artery.
Balloon angioplasty is a commontreatment of ischemic
heart disease which involves the inflation of a balloon in a
clogged blood vessel in order to open the blocked blood
vessel. Unfortunately, this method of treatment results in
injury to the endothelial cells lining the inner walls of blood
vessels often leading to restenosis. The peptides described
herein can be employed to induce proliferation and migra-
tion of the endothelial cells located at the periphery of the
balloon induced damaged area in order to cover the luminal
surface of the vessel with a new monolayer of endothelial
cells, hoping to restore the original structure of the blood
vessel. Coronary angioplasty is frequently accompanied by
deploymentof an intravascular stent to help maintain vessel














heparin to prevent thrombosis until the new channel formed
by the stent can endothelialize. The peptides described
herein can be applied directly to the stent, using methods
knownto those of skill in the art. The peptides can be locally
applied or systemically administered to enhance endothe-
lialization of the vessel or vessel wall and/or to modulate
other processes to inhibit or reduce thrombosis and resteno-
sis.
The present invention preferably employs synthetic or
naturally derived polypeptide agonists of thrombin receptor
mediated events. Both of these classes of agents possess a
thrombin receptor binding domain which includes a segment
of the polypeptide that is capable of selectively binding to
the high-affinity thrombin receptor. This segment of the
polypeptide includes a sequence of amino acids homologous
to a tripeptide cell binding domain of fibronectin.
In addition to the thrombin receptor binding domain, the
stimulatory (agonistic) polypeptides possess a sequence of
amino acids having sequences derived from the N-terminal
amino acids of a dodecapeptide previously shown to be
highly conserved among serine proteases. However, the
inhibitory polypeptides do not include these serine esterase-
conserved sequences.
For example, the invention provides a numberofpolypep-
tides useful in promoting cardiac tissue repair. For such
applications, the invention provides a polypeptide derivative
of thrombin (or a functional equivalent of such a derivative)
which has a thrombin receptor binding domain as well as a
domain with a serine esterase conserved sequenceofat least
12 amino acids. The invention also provides a polypeptide
compound of at least 23 L-amino acids which has both a
thrombin receptor binding domain and a domain with a
serine esterase conserved amino acid sequence.
In one embodiment, the invention provides for several
polypeptides containing specific amino acid sequences, such
as a polypeptide compoundin which the thrombin receptor
binding domain includes the L-amino acid sequence Arg-
Gly-Asp-Ala (SEQ ID NO: 1) together with the serine
esterase conserved amino acid sequence, Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 2). In a
preferred embodiment, the polypeptide compound includes
the L-amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-
Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-
Pro-Phe-Val (SEQ ID NO:3). The polypeptide compound
can be modified by amidation of the carboxy terminus. For




The invention also provides for a pharmaceutical compo-
sition for promoting tissue repair which includes a thera-
peutically effective concentration of any of the compounds
described above combined with a pharmaceutically accept-
able excipient. Typically, such compositions include, for
example, sufficient concentrations of the polypeptides to
effect a stimulatory action on the thrombin receptor as
demonstrated herein. Thus, such compositions should typi-
cally include sufficient concentrationsto obtain levels of the
polypeptides at the target site which are shown in vitro to
stimulate the receptor. When endogenouslevels of a sec-
ondary signal are believed to be inadequate, compositions
may be employed which further include the addition of a
therapeutically effective concentration of VEGF, alpha-
thrombin, gamma-thrombin or other growth factors. Such
combinations may exert an additive or synergistic effect. In
certain cases, if tissue damage is so extensive that cells
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capable of responding to the polypeptides are not present in
sufficient quantities, it is expected that responsive cells could
be co-injected to provide a therapeutically effective combi-
nation.
Suitable carriers also provide for release of the active
ingredient and preferably for a slow, sustained release over
time at the target site. A numberof synthetic biodegradable
polymers can serve as carriers with sustained release char-
acteristics. Examples of these polymers include poly
a-hydroxy esters such as polylactic acid/polyglycolic acid
homopolymers and copolymers, polyphosphazenes
(PPHOS), polyanhydrides and poly(propylene fumarates).
Polylactic acid/polyglycolic acid (PLGA) homo and
copolymers are well known in the art as sustained release
vehicles. The rate of release can be adjusted by the skilled
artisan by variation of polylactic acid to polyglycolic acid
ratio and the molecular weight of the polymer (see
Anderson, et al., Adv. Drug Deliv. Rev. 28:5 (1997), the
entire teachings of which are incorporated herein by
reference). The incorporation of poly(ethylene glycol) into
the polymeras a blend to form microparticle carriers allows
further attenuation of the release profile of the active ingre-
dient (see Cleek et al., J. Control Release 48:259 (1997),the
entire teachings of which are incorporated herein by
reference). PGLA microparticles are often mixed with plu-
ronic gels or collagen to prevent aggregation and to make the
microparticles suitable for direct injection.
PPHOSpolymers contain alternating nitrogen and phos-
phorous with no carbon in the polymer backbone, as shown






The properties of the polymer can be adjusted by suitable
variation of side groups R and R' that are bonded to the
polymer backbone. For example, the degradation of and
drug release by PPHOS can be controlled by varying the
amount of hydrolytically unstable side groups. With greater
incorporation of either imidazolyl or ethylglycinato substi-
tuted PPHOS,for example, an increase in degradation rate
is observed (see Laurencin et al., J Biomed Mater. Res.
27:963 (1993), the entire teachings of which are incorpo-
rated herein by reference), thereby increasing the rate of
drug release.
Polyanhydrides, shown in Structural Formula (II), have
well defined degradation and release characteristics that can
be controlled by including varying amounts of hydrophobic
or hydrophilic monomers such as sebacic acid and 1,3-bis
(p-carboxyphenoxy)propane (see Leong et al., J. Biomed.
Mater. Res. 19:941 (1985),the entire teachings of which are





Poly(propylene fumarates) (PPF) are highly desirable
biocompatible implantable carriers because they are an
injectable, in situ polymerizable, biodegradable material.
“Injectable” means that the material can be injected by
















and gels. PPF, combined with a vinyl monomer (N-vinyl
pyrrolidinone) and aninitiator (benzoyl peroxide), forms an
injectable solution that can be polymerized in situ (see
Suggs et al., Macromolecules 30:4318 (1997),Peter et at., J
Biomater. Sci. Poly,. Ed. 10:363 (1999) and Yaszemskietat.,
Tissue Eng. 1:41 (1995), the entire teachings of which are
incorporated herein by reference).
As used herein, a therapeutically effective concentration
is defined as a concentration of the particular agent which
provides a satisfactory increase in the rate of repair or
angiogenesis or which provides a satisfactory reduction or
inhibition of restenosis or vascular occlusion. Again, such
concentrations are believed to correspondto levels sufficient
to elicit a stimulation of the high-affinity thrombin receptor
in vitro. However, it is believed that the compositions will
prove most effective when the stimulatory (agonistic)
polypeptides are present at a concentration of from 0.1 4M
to 10 uM.
For purposesof the present invention, a thrombin deriva-
tive is defined as any molecule with an amino acid sequence
derived at least in part from that of thrombin, whether
synthesized in vivo or in vitro. Accordingly, a thrombin
derivative, as referred to herein, designates a polypeptide
molecule which comprises fewer amino acids than throm-
bin.
A physiologically functional equivalent of a thrombin
derivative encompasses molecules which differ from throm-
bin derivatives in particulars which do notaffect the function
of the thrombin receptor binding domain or the serine
esterase conserved amino acid sequence. Such particulars
may include,but are not limited to, conservative amino acid
substitutions and modifications, for example, amidation of
the carboxyl terminus, acetylation of the amino terminus,
conjugation of the polypeptide to a physiologically inert
carrier molecule, or sequencealterations in accordance with
the serine esterase conserved sequences.
A thrombin receptor binding domain is defined as a
polypeptide sequence which directly binds to the thrombin
receptor and/or competitively inhibits binding between
high-affinity thrombin receptors and alpha-thrombin.
A domain having a serine esterase conserved sequence
comprises a polypeptide sequence containing at least 4-12
of the N-terminal amino acids of the dodecapeptide previ-
ously shownto be highly conserved amongserine proteases
(Asp-X,-Cys-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val-SEQ
ID NO:5); wherein X, is either Ala or Ser; X, is either Glu
or Gln; and X, is either Phe, Met, Leu, His, or Val).
A stimulatory polypeptide is defined as a polypeptide
derivative of thrombin, or a physiologically functional
equivalent thereof, having the ability to both bind to and
stimulate the thrombin receptor. Therefore, the stimulatory
peptides will include both a thrombin receptor binding
domain and a domain with a serine esterase conserved
amino acid sequence.
The invention is illustrated by the following examples,
which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1
TP508 Stimulates the Proliferation and Migration
of Human Endothelial Cells In Vitro
To determine if TP508 could directly induce proliferation
of endothelial cells, human microvascular endothelial cells
were purchased from Clonetics, plated on tissue culture
grade plastic in 24 well culture dishes and serum starved for
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24 hours. Cells were stimulated in medium with or without
TP508 for 48 hours, at which time proliferation was assessed
using a direct cell count. As shown in FIG. 1, TP508
stimulated proliferation of microvascular endothelial cells
by 30 to 50% overthose treated in medium alone (1.0 ug/ml
TP508). This effect appeared to be specific since the growth
of smooth muscle cells isolated from rat aorta was not
affected by TP508.
TP508 effects on migration of human endothelial cells
was assessed using an in vitro monolayer wound assay in
which endothelial cells were plated in 35 mm culture dishes
and allowed to grow to near confluency for three days, at
which time the monolayer was “wounded” by scraping
across the center of the dish with a rubber policeman to
remove a bandof cells. Photographs were takenat this point,
and the cells were then treated with fresh medium alone or
medium containing various concentrations of TP508 and
allowed to grow for an additional 48 hours. The cells were
re-photographed, and the distance that the endothelial cells
migrated into the wounded area was measured. As shown in
FIG. 2, TP508 stimulated migration of endothelial cells,
even whenthe cells were cultured on plastic alone.
These studies demonstrated that TP508 has direct angio-
genic effects on human endothelial cells causing increased
proliferation and migration in vitro. Additional studies indi-
cate that exposure of endothelial cells to TP508 has a
protective effect to prevent death of cells caused by oxida-
tive exposure. This protective effect may also contribute to
processes of re-endothelialization and angiogenesis.
Example 2
TP508 Stimulates Angiogenesis In Vitro in a
Chorioalloantoic Membrane Model
Studies with full dermal surgical incisions and open
excisional woundsin the backs of rats showed that a single
topical application of TP508 stimulates revascularization
and the patency of blood vessels traversing a surgical
incision. Two surgical incisional wounds were made on the
back of a rat. One wound wastreated with a single appli-
cation of TP508 (0.1 yg); the other was untreated. Blood
vessels were attracted to the treated wound rather than the
control.
Addition of TP508 to agar disks placed on the chorioal-
loantoic membraneof chicken embryosresulted in an angio-
genic outgrowth of blood vessels. Blood vessels were stimu-
lated to grow into agar disks containing TP508. There was
also an increase in collateral vessel outgrowth in vessels
distal to the plug similar to that observed with other angio-
genic factors.
Example 3
TP508 Showed Efficacy in Treating Myocardial
Ischemia in a Porcine Model.
Yucatan minipigs had toroid shaped ameroid occluders
placed on their proximal left circumflex arteries. The
ameroid imbibed water over time, causing constriction of
the vessel. Occlusion wasverified four weeks after surgery
by contrast enhanced angiography. At that time, each ani-
mal’s chest was reopened, whereuponthe region of ischemia
wasinjected with a slow release formulation of TP508,i.e.,
TP508-containing PGLA microspheres, suspended in a Plu-
ronic gel. The PLGA microspheres, which were prepared as
described in Example 6, gave an initial burst release of drug













release for another 3-4 days, by which time 80% of the load
had been released. The gel used was 30% w/w Pluronic F68
in 0.9% saline. To each milliliter of gel, on ice to reduce the
viscosity, 3.3 mg of PLGA microspheres were added imme-
diately before injection. This gave a TP508 dose of 100
ug/ml of gel, which was injected into ten sites (100 ul per
site) in the ischemic area. Controls received PLGA micro-
spheres in Pluronic gel without TP508. Baseline, and post-
treatment angiograms and echocardiograms were obtained.
Indices for myocardial wall thickening and cardiac ejec-
tion fraction showed trends that TP508 treated animals
tolerated dobutamine-induced stress better than controls.
After three weeks, the animals were evaluated with contrast
enhanced echocardiography. Initial results on this limited
numberof animals demonstrated that TP508 treated animals
under dobutamine stress had a slightly larger increase in
ejection fraction and better maintained wall thickening com-
pared to controls. Thus, this treatment appears to help restore
functionality to the ischemic heart muscle.
Example 4
TP508 Stimulates Myocardial Revascularization in
a Rabbit Model
TP508, formulated in sustained release PLGA
microspheres, was injected into ischemic rabbit myocar-
dium. An ameroid occluder was placed over the lateral
division of the left main coronary artery of two rabbits just
inferior to the A-V groove, as described in Operschall et al.,
J. Appl. Physiol. 88:1438 (2000). Two weeks after
placement, the animals’ chests were reopened. In one
animal, TP508 microspheresin pluronic gel (as described in
Example 3) were injected into eight discrete locations
within, and around, the area served by the occluded vessel.
The other animal served as an untreated control. Approxi-
mately four weeks post-injection, the animals were sacri-
ficed and their hearts fixed in 10% buffered formalin for 24
hours. Hearts were then sectioned acrossthe area of interest
and stained by hematoxylin-eosin and immunolabelled
against Von Willebrand Factor (vWF), an endothelial cell
marker.
Histology demonstrated that the control animal hadsig-
nificant fibrosis in the area served by the occluder. The
TP508 treated heart, on the other hand, had healthy appear-
ing myocardium with a larger numberof functional capil-
laries with obvious red bloodcells.
Example 5
TP508 Suppresses Restenosis in a
Hypercholesterolemic Rabbit Model
This procedure was designed to provide a system for
testing the efficacy of a Test Sample to inhibit neointimal
formation and vascular occlusion following angioplasty in
hypercholesterolemic New Zealand White Rabbits. The ani-
mals were fed a high fat diet consisting of 0.5% cholesterol
and 2.0% peanut oil for 3 weeks. The animals were pre-
treated 24 hours prior to surgery; the iliac artery was injured
with balloon angioplasty as described; and the animals were
are treated with TP-508 for 7 days. The animals were
maintained on a high fat diet for 4 weeks. Angiography was
conducted prior to balloon angioplasty and at termination of
the experiment. The injured and uninjured iliac arteries were
harvested and prepared for histology. Morphometric mea-
surements were made of the lumen, the neointima (if
present), and the tunica media.
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Test samples of TP-508 were dissolved/diluted in asterile,
pyrogen-free saline to the desired concentration and admin-
istered by intravenous injection in a 0.2 ml volumeone day
prior to surgery, the day of surgery, and for 6 successive days
post surgery.
A 5 cm midline neck incision was made and the right
carotid was exposed, proximately ligated, and incised. A 4 Fr
Berman Balloon Angiographic Catheter was then introduced
into the aorta. A5 Fr sheath was introducedinto the aorta via
the 4 Fr Berman Balloon Angiographic Catheter. Three ml of
blood was collected for cholesterol count. The rabbit was
then injected with heparin and more anesthetics (if
necessary). To visualize the iliac arteries, 6 ml of Hypaque
76% mixed with 4 mlsterile saline was injected through the
catheter. Imaging was acquiredoftheiliac arteries (imageis
marked with grid and scissors are placed on theright side).
The 4 Fr Berman Balloon Angiographic Catheter was
removed from the sheath. A 0.014"/3.0 mmx20.0 mm/120
cm Balloon Catheter was then inserted through the sheath
into the aorta and to the iliac artery. The balloon wasinflated
3 times at 10 ATM for 30 seconds with 1 minute intervals.
The catheter and sheath were then removed. The right
carotid artery was ligated with 3.0 silk sutures. The neck
incision was closed with PDS and the skin stapled and
dressed with double antibiotic ointment.
The test sample(s) or control sample(s) were then admin-
istered to the rabbit. The Test Sample was diluted in the
following manner: 0.3 ml of saline was drawn into a 1.0 ml






tunica media of the vessels was measured similarly. These
values were then normalized by summingthe area of these
two regions and dividing that result by the area of a normal
(un-injured) media found within the same histological slide
series. It was verified that there was no significant difference
between groups in the areas found for the uninjured media.
When comparing treated animals against controls, the
extent of restenosis was analyzed via three distinct methods:
the “single worst value” method, the “average lesion thick-
ness” method, and the “average ofall sections” method. The
“single worst value” method compares the maximum rest-
enosis value obtained between operated vessels. The “aver-
age lesion thickness” method compares the averages all
abnormal points within a well-defined region of injury
between operated vessels. Lastly, the “average of all sec-
tions” method comparesthe average thicknessofall samples
measured, regardless of whether or not they appeared to be
part of the lesion. The meansofthese results were tested for
statistical significance via the Student’s T-test.
Data Summary
All data analysis was completed using the two-tailedt-test
assuming unequal variances. Alpha is 0.05 and the mean
difference is assumed to be 0. Each analysis includes n=7 for
treated and n=9 for saline control. The results are summa-
rized in the following Table 1. The “difference” value shown
relates to the percentage change of the treated as compared




Technique: Single Worst Value Average Lesion Thickness Average of All Sections
Measured Area: Treated Controls Diff. Treated Controls Diff. Treated Controls Diff.
Neointima 202 332 -39%* 158 .245 -36% 117 185 -37%*
Media 113 133 -15% 123 152 -19% 116 140 -17%
Neo + Media/ 4.56 7.73 -41%* 4.18 5.87 -29%* 3.49 5.55 -37%*
Uninjured Media
the TP-508 vile. After the TP-508 dissolved, 0.25 ml of the CONCLUSION
solution was removed and administered. The cannulation
tube was then flushed with saline. If the rabbit was a control,
0.2 ml of saline was injected and flushed with additional
saline. The rabbit also received 0.3 ml of Buprenorphine via
subcutaneous injection.
After surgery, the rabbit was allowed time to becomealert
while resting on the heating pad. The rabbit was then
returned to his cage and allowed food and water ad libitum.
The rabbits were maintained on the diet for 4 additional
weeks until sacrifice.
Four weekspost-procedure, both iliac arteries were fixed
in situ, harvested and prepared for histology. Digital images
were then captured ofthe serial histological sections spaced
approximately one millimeter apart and morphometric mea-
surements were made of the lumen, the neointima (if
present) and the tunica media throughout the region of
injury.
Histology Summary
Morphohistological analysis of 19 samples were com-
pleted using Image-Pro Plus and Excel software. Of the 19
samples, 2 demonstrated compromise of the external elastic
laming One sample of the 19 appeared to require additional
sectioning. Therefore, 16 samples were compared compris-
ing 7 treated and 9 saline controls.
The thickness of the restenotic lesion was determined by






The data shows that TP-508 significantly suppressed
restenosis and vascular occlusion in the hypercholester-
olemic rabbit model. This result is robust in that it is
independent of the technique chosen for quantifying the
results.
Example 6
Preparation of Polylactic Acid/Polyglycolic Acid
Copolymer Microspheres of TP508
A double emulsion technique was used to prepare micro-
spheres of polylactic acid/polyglycolic acid copolymer
(PLA/PGA)containing TP508. Briefly, the matrix compo-
nents were dissolved in methylene chloride and TP508 was
dissolved in water. The two were gradually mixed together
while vortexing to form a water-in-oil (W/O) emulsion.
Polyvinyl alcohol (0.3% in water) was added to the emulsion
with further vortexing to form the second emulsion (O/W),
thereby forming a double emulsion: an O/W emulsion
comprised of PLA/PGAdroplets, and within those droplets,
a second disperse phase consisting of TP508 in water. Upon
phase separation, the PLA/PGA droplets formed discrete
microspheres containing cavities holding TP508. To cause
phase separation of the microspheres, a 2% isopropyl alco-
hol solution was added. The particles were collected by
centrifugation, and then lyophilized to remove residual
moisture. The composition of the matrix was varied to form





Composition of different microsphere formulations
Polymer % % poly-ethylene
Formulation PLA:PGA M.Wt. TP508 glycol
A 50:50 46,700 5 0)
B 50:50 7,200 5 0)
Cc 50:50 46,700 5 5
D 50:50 46,700 5 0)
E 75:25 120,000 5 0)
 
The mean diameter of the microspheres was measured in
a Coulter counter and the drug entrapment efficiency was 45
measured by spectrophotometric assay at 276 nm following
dissolution of a weighed sample of microspheres in meth-





Formulation diameter and drug entrapment efficiency










To measure TP508 release from the different PLA/PGA
matrices, 20 mg of microspheres were placed in 1.0 ml of
PBS contained in 1.5 ml polypropylene microcentrifuge
tubes. Tubes were incubated at 37° C. and shaken at 60 rpm.
Atvarious times, the tubes were centrifuged and the super-
natant containing released TP508 was removed and frozen
for subsequent analysis. Fresh PBS wasaddedto the micro-
spheres and incubation was continued. TP508 in the super-
natant was measured by absorbance at 276 nm. For each
formulation, quadruplicate release determinations were per-
formed. Formulations B and D showed nodetectable drug
release during 28 days of incubation at 37° C. The remaining
formulations all released detectable amounts of TP508,
although in all cases the amountof drug released fell below
detectable limits (<1 “g/mg matrix/day) within 3-4 days.
Formulations A and C showedthe greatest release of TP508,
releasing 60-80% of the entrapped drug over 3-4 days. The
formulation with the fastest release kinetics, C, was chosen
for further testing in in vivo studies described in Example 3
and Example 4.
While this invention has been particularly shown and
described with references to preferred embodimentsthereof,
it will be understood by those skilled in the art that various
changes in form and details may be made therein without
departing from the scope of the invention encompassed by
the appended claims.
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 5
<210> SEQ ID NO 1
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: human fragment of thrombin
<400> SEQUENCE: 1
Arg Gly Asp Ala
1
<210> SEQ ID NO 2
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: human fragment of thrombin
<400> SEQUENCE: 2
Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Phe Val
1 5 10
<210> SEQ ID NO 3
<211> LENGTH: 23
<212> TYPE: PRT






<223> OTHER INFORMATION: human fragment of thrombin
<400> SEQUENCE: 3
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10




















OTHER INFORMATION: valine is amidated as CONH2
<400> SEQUENCE: 4
15
OTHER INFORMATION: C-terminal amidated fragment of human thrombin
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 5
<211> LENGTH: 12
<213> ORGANISM: Artificial Sequence
<220> FEATURE:












<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or
<400> SEQUENCE: 5






1. A method for promoting cardiac tissue repair compris-
ing administering to the cardiac tissue a therapeutically
effective amount of the peptide Ala-Gly-Tyr-Lys-Pro-Asp-
Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-
Gly-Pro-Phe-Val-NH, (SEQ ID NO:4).
2. The method of claim 1 wherein the peptide is admin-
istered during or following cardiac surgery.
3. The method of claim 1 wherein the peptide is admin-
istered by injection into the cardiac tissue.
4. The method of claim 1 wherein a sustained release
formulation comprising the peptide is administered to the
cardiactissue.
5. The method of claim 4 wherein the sustained release
formulation is a polylactic acid/polyglycolic acid micropar-
ticles comprising the peptide.
6. A method of stimulating revascularization of cardiac
tissue comprising administering to cardiac tissue comprising




amount of the peptide Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val-NH, (SEQ ID NO:4).
7. Amethod of inhibiting restenosis in a patient following
balloon angioplasty, said method comprising administering




8. The method of claim 7 wherein the peptide is coated
onto a balloon angioplasty catheter.
9. The method of claim 7 wherein the peptide is admin-
istered systemically.
10. The method of claim 7 wherein the peptide is admin-
istered locally to a balloon induced damagedarea of a blood
vessel.
11. The method of claim 7 wherein a stent coated with the




12. A stent coated with the peptide Ala-Gly-Tyr-Lys-Pro- peutically effective amount of the peptide Ala-Gly-Tyr-Lys-
Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser- Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-CysGlu-Gly-Asp-
Gly-Gly-Pro-Phe-Val-NH, (SEQ ID NO:4). Ser-Gly-Gly-Pro-Phe-Val-NH, (SEQ ID NO:4).
13. Amethodof inhibiting vascular occlusion in a patient,
said method comprising administering to the patient a thera- * RR RF
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